c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma
Neelu Puri(Rockford University), Ravi Salgia(City Of Hope National Medical Center)
Cited by 154
Related Papers
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
|Journal for ImmunoTherapy of Cancer|2018|1.3k
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
|Journal of Clinical Oncology|2011|551